John W. Walsh Alpha-1 Home Infusion Act of 2025

This bill would make Medicare cover at-home treatment for people with alpha‑1 antitrypsin (AAT) deficiency, a protein problem that can lead to lung disease. It adds Medicare Part B coverage for “augmentation therapy” given in the patient’s home by qualified home infusion therapy suppliers . To qualify, the person must have severe hereditary AAT deficiency with emphysema, be under the care of a doctor, nurse practitioner, or physician assistant, be enrolled in both Part A and Part B, and not be in a Medicare Advantage plan.

Medicare would also pay these suppliers for IV administration kits and nursing services tied to the therapy, for up to 2 hours of care. These changes would apply to items and services provided on or after January 1, 2027.

• Who is affected: Medicare patients with severe hereditary AAT deficiency and emphysema, under the care of a physician, nurse practitioner, or physician assistant; enrolled in Parts A and B only (not Medicare Advantage).
• What changes: Part B covers at‑home augmentation therapy delivered by qualified home infusion therapy suppliers; Medicare pays for IV kits and nursing for up to 2 hours tied to the therapy .
• When: Starts for services on or after January 1, 2027.